Research on Cell Death in Cancer Immunotherapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 25 December 2024 | Viewed by 51

Special Issue Editor


E-Mail Website
Guest Editor
1. Center for Biochemistry, Medical Faculty, University of Cologne, 50931 Cologne, Germany
2. Centre for Cell Death, Cancer, and Inflammation (CCCI), UCL Cancer Institute, University College London, London WC1E 6DD, UK
Interests: TNF; FasL; TRAIL; LUBAC; TBK1; apoptosis; necroptosis

Special Issue Information

Dear Colleagues,

In this Special Issue we will, on the one hand, summarize the current knowledge, including recently gained crucial insights, on the role of cell death in cancer immunotherapy and, on the other, point towards exciting future opportunities for discovery in this highly exciting field. In addition to discussing the role of different death receptor–ligand systems and their role in enabling or, indeed, preventing cancer immunotherapy, we will also discuss how different factors that have recently emerged as decisive in terms of preventing or enabling cancer immunotherapy are thought to exert their impact on the efficacy of cancer immunotherapy. Finally, we will discuss how different modalities of programmed cell death may differentially affect the outcome of cancer immunotherapy.

Thereby, this review series will provide a timely and highly constructive collection of reviews that complements the current literature in this exciting field of tumor immunobiology. We believe it will become a go-to series for anyone interested in grasping the status quo with regard to both current knowledge of and future research directions on the role of cell death in cancer immunotherapy.

Best wishes

Prof. Dr. Henning Walczak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • TNF
  • FasL
  • TRAIL
  • death receptor–ligand systems
  • LUBAC
  • RNF31
  • cIAP1/2
  • TBK1
  • IKK
  • RIPK1
  • RIPK3
  • apoptosis
  • necroptosis
  • pyroptosis
  • ferroptosis

Published Papers

This special issue is now open for submission.
Back to TopTop